Company: TNRSF
Filing Date: 2025-04-07
Form Type: 6-K
Source: 0001171843-25-002038
Chunk: 1

Company: TENARIS SA
Filing Date: 2025-04-07
Form: 6-K
Chunk 1
---
 will be held immediately after the adjournment
of the Annual General Meeting of Shareholders. Both meetings (the “Meetings”) will be held at the Company’s registered
office located at 26, Boulevard Royal, 4 Floor, L-2449 Luxembourg, Grand-Duchy of Luxembourg.

At the Annual General Meeting of Shareholders, shareholders will vote on
the items listed below under the heading “Agenda for the Annual General Meeting of Shareholders”. At the Extraordinary General
Meeting of Shareholders, shareholders will vote on the items listed below under the heading “Agenda for the Extraordinary General
Meeting of Shareholders”.

Agenda for the Annual General Meeting of Shareholders

| 3. | Approval of the Company’s annual accounts as at 31st December 2024. |

| 6. | Election of the members of the Board of Directors. |

| 10. | Authorization to the Company, or any subsidiary, to purchase, acquire or receive securities of the Company,       
 in accordance with Article 49-2 of the Luxembourg law of 10 August 1915 and with applicable laws and regulations. |

| 11. | Authorization to the Board of Directors to cause the distribution of all shareholder communications, including                             
 its shareholder meeting and proxy materials and annual reports to shareholders, by such electronic means as is permitted by any applicable 
 laws or regulations.                                                                                                                       |

Agenda for the Extraordinary General Meeting of Shareholders

| 1. | Approval of (a) the cancellation of 90,762,598 ordinary shares held in treasury, acquired by the Company                                     
 throughout (i) the second, third and fourth tranches of the share buyback program, which ran from 6th November 2023 to 2nd                   
 August 2024, and (ii) the follow-on share buyback program, which ran from 11th November 2024 to 4th March 2025,                              
 and (b) consequential reduction of the issued share capital of the Company by an amount of US$ 90,762,598 so as to bring it from its current 
 amount of US$1,162,757,528 to US$ 1,071,994,930, represented by 1,071,994,930 ordinary shares with a nominal value of US$1.00 per share.     |

| 2. | Decision on the renewal of the authorized share capital of the Company and related authorizations and 
 waivers by: